Group 1 - The pharmaceutical sector in both A-shares and Hong Kong stocks experienced a collective decline on September 26 [1] - In A-shares, Sunflower dropped by 10%, while Guangsheng Tang and Aosaikang fell over 8%. Other companies like Jimin Health, Hanyu Pharmaceutical, Wanbangde, Hengrui Medicine, and Huiyu Pharmaceutical also saw declines [1] - In Hong Kong stocks, WuXi AppTec decreased by over 5%, BeiGene fell by more than 4%, and Fosun Pharma dropped nearly 2% [1]

Core Viewpoint - The pharmaceutical sector in the Asia-Pacific market experienced a significant decline, with various indices showing notable drops, particularly in the weight loss drugs, innovative drugs, and CRO sectors [1][2]. Group 1: Market Performance - The A-share pharmaceutical and biotechnology sector saw a downturn, with weight loss drug index dropping by 1.56%, innovative drug index by 0.61%, and CRO index by 0.40% [2]. - Individual stocks such as Sunflower (向日葵) fell over 10%, while Aosaikang (奥赛康) and Guangshengtang (广生堂) also experienced significant declines of 9.02% and 6.56% respectively [3]. Group 2: Hong Kong and Japan Market Impact - The Hang Seng Biotechnology Index opened down nearly 2% and continued to decline, with companies like MicroPort Medical (微创医疗) and BeiGene (百济神州) showing notable drops of 5.47% and 4.75% respectively [4]. - In Japan, companies such as Sumitomo Pharma (住友制药) and Daiichi Sankyo (第一三共) also faced declines exceeding 4% and 3% respectively [4]. Group 3: External Factors - The recent announcement by U.S. President Trump regarding a new round of high tariffs on imported goods, including a punitive 100% tariff on patented and branded pharmaceuticals, is expected to impact the pharmaceutical industry significantly [5].

Market Overview - On September 25, the medical services sector rose by 0.78%, with Bid Pharma leading the gains [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Top Gainers in Medical Services - Bid Pharma (688073) closed at 79.56, up 6.61% with a trading volume of 18,000 hands and a transaction value of 141 million [1] - Jiuzhou Pharmaceutical (603456) closed at 19.46, up 5.65% with a trading volume of 749,100 hands and a transaction value of 1.484 billion [1] - Yaokang Bio (688046) closed at 19.10, up 3.24% with a trading volume of 39,200 hands and a transaction value of 74.36 million [1] Top Losers in Medical Services - Baicheng Pharma (301096) closed at 60.30, down 6.37% with a trading volume of 94,600 hands and a transaction value of 583 million [2] - Haochen Medical (002622) closed at 3.83, down 3.04% with a trading volume of 465,400 hands and a transaction value of 181 million [2] - Chengda Pharmaceutical (301201) closed at 29.79, down 2.84% with a trading volume of 33,300 hands and a transaction value of 100 million [2] Capital Flow Analysis - The medical services sector saw a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 28.43 million [2] - Jiuzhou Pharmaceutical had a net inflow of 191 million from institutional investors, but a net outflow of 93.86 million from retail investors [3] - Bid Pharma experienced a net inflow of 19.49 million from institutional investors, with a net outflow of 8.87 million from retail investors [3]

Core Insights - The new "new three items" in China's economy are robotics, artificial intelligence (AI), and innovative pharmaceuticals, which are now driving high-quality economic development [1][2] - The market for these sectors is experiencing significant growth, with A-share companies in robotics and AI seeing substantial increases in market capitalization [2][3] - China's position in these sectors is evolving from "catching up" to "leading," particularly in robotics, while AI is in a competitive position and innovative pharmaceuticals are gaining international recognition [3][4] Robotics Sector - The humanoid robotics field is viewed as a potential game-changer, with leading A-share companies like Huichuan Technology exceeding a market cap of 200 billion and significant first-day gains for companies like Sanxie Electric [2][3] - The robotics industry is advancing rapidly, with China entering the global first tier, although high-end components still require imports [3] Artificial Intelligence Sector - Several companies in the AI sector have market capitalizations exceeding 100 billion, with strong demand for AI computing chips and infrastructure leading to impressive performance [2][3] - China has strong competitiveness in application areas like computer vision and speech recognition, but still faces challenges in foundational chips and ecosystem development [3] Innovative Pharmaceuticals Sector - Companies like Hengrui Medicine are approaching a market cap of 500 billion, with others like WuXi AppTec and Innovent Biologics also exceeding 100 billion [2] - The innovative pharmaceutical sector is experiencing explosive growth in international transactions, indicating improved R&D capabilities, though challenges remain in target discovery and basic research translation [3] Market Dynamics - The shift from traditional growth drivers to technology-intensive, high-value-added production is essential for overcoming the challenges of traditional industries [1][3] - The advantages of a large-scale market, strong engineering capabilities, and an improving policy environment are critical for these sectors [3] Policy Recommendations - There is a need for policies that promote data openness, optimize review processes, and increase investment in computing infrastructure [3] - Focus on interdisciplinary talent development and encourage long-term capital investment in foundational research is essential for sustaining growth [3]

Core Viewpoint - The article emphasizes that the new "new three items" for China's economy are robotics, artificial intelligence (AI), and innovative pharmaceuticals, which are now driving high-quality economic growth, surpassing traditional sectors like finance and real estate [1][2]. Group 1: Robotics - The robotics sector, particularly humanoid robots, is seen as the next potential world-changing technology after computers, smartphones, and electric vehicles. Leading companies like Huichuan Technology have a market capitalization exceeding 200 billion, with some stocks experiencing significant price increases [2]. - China is making rapid progress in robotics, moving from "catching up" to "leading" on a global scale, with a complete industrial chain and the largest market, although high-end components still rely on imports [2][3]. Group 2: Artificial Intelligence - The AI sector has several companies with market capitalizations over 100 billion, focusing on AI computing chips and infrastructure. Companies like Cambricon and Industrial Fulian are experiencing explosive growth in orders and performance [2]. - China is competitive in application-level AI, particularly in computer vision and speech recognition, but still lags in foundational chips and ecosystem frameworks [3]. Group 3: Innovative Pharmaceuticals - The innovative pharmaceutical sector is witnessing significant growth, with companies like Hengrui Medicine nearing a market cap of 500 billion. The business model is shifting from "burning money" to "making money," gaining global market recognition [2]. - China's innovative drugs are moving from "following" to "keeping pace," with explosive growth in overseas transactions, although challenges remain in target discovery and basic research translation [3]. Group 4: Advantages and Challenges - China's advantages include a large-scale market providing scenario dividends, strong engineering and industrialization capabilities, and a continuously improving policy environment. However, there are risks of being "choked" if key segments are controlled by external entities [3]. - The article suggests that policy improvements are needed to create an open data ecosystem, optimize review processes, and increase investment in foundational research [4].

Market Overview - On September 25, A-shares opened slightly lower, with the three major indices showing a downward trend. The Shanghai Composite Index decreased by 0.06%, the Shenzhen Component Index fell by 0.30%, and the ChiNext Index dropped by 0.45% [2][4]. Industry Performance - The non-ferrous metals, media, electric equipment, and pharmaceutical sectors showed notable gains, with the nuclear fusion, copper industry, superconductors, and CRO concept stocks being particularly active. In contrast, semiconductor, memory, and photolithography sectors experienced declines [2][3]. Copper Industry Insights - The copper industry index led the gains, with stocks such as Jingyi Co., Northern Copper, and Luoyang Molybdenum hitting the daily limit. Other companies like Electric Alloy, Tongling Nonferrous Metals, and Jiangxi Copper also saw increases [4][5]. - A recent landslide at Freeport McMoRan's Grasberg mine in Indonesia has raised global copper prices and triggered supply chain concerns. The mine accounts for approximately 3% of global copper supply, and the incident is expected to impact global supply significantly in the fourth quarter [6]. Nuclear Fusion Sector - Nuclear fusion concept stocks experienced a strong rally, with companies like Hezhong Intelligent and Farsen hitting the daily limit, while others like Hahuan Huadong and Zhongzhou Special Materials rose over 10% [6][7]. - China Fusion Energy Co., known as the "national team" for controllable nuclear fusion, aims to focus on overall design, technology verification, and digital R&D, establishing a technology R&D platform and capital operation platform [10]. Company Specifics - On September 25, Upwind New Materials saw its stock price surge to 132.1 CNY, reaching a daily limit increase of 20%, with a total market value of 53.3 billion CNY [11][12]. - The company announced the completion of a share transfer, with Zhiyuan Hengyue and Zhiyuan Xinchuang holding a combined 29.99% stake, making Zhiyuan Hengyue the new controlling shareholder. An offer to acquire an additional 37% of shares at 7.78 CNY per share is also planned, requiring up to 1.161 billion CNY [13].

Group 1 - The CRO index experienced an intraday increase of 2.01%, indicating strong market performance in the sector [1] - Jiuzhou Pharmaceutical reached its daily limit up, showcasing significant investor interest [1] - Zhaoyan New Drug and Aopu Mai saw respective increases of 3.49% and 3.40%, reflecting positive momentum among key players [1] - WuXi AppTec and Kelai Ying both recorded gains exceeding 2.5%, further highlighting the active performance of the CRO sector [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年9月23日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 FANGDA PARTNERS http://www.fangdalaw.com 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 2025 年第二次临时股东大会的法律意见书 致：无锡药明康德新药开发股份有限公司 上海市方达（北京）律师事务 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年9月23日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-064 无锡药明康德新药开发股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在 ...

無錫藥明康德新藥開發股份有限公司 章程 （2025年第二次修訂） 無錫藥明康德新藥開發股份有限公司章程 第一章 總則 第一條 為維護公司、股東、職工和債權人的合法權益，規範無錫藥明康德新藥開發股 份有限公司（以下簡稱「公司」或「本公司」）的組織和行為，根據《中華人民共和國公司法》 （以下簡稱「《公司法》」）、《中華人民共和國證券法》（以下簡稱「《證券法》」）、《境內企業 境外發行證券和上市管理試行辦法》、《上市公司章程指引》、《上海證券交易所股票上 市規則》（以下簡稱「《上交所上市規則》」）、《香港聯合交易所有限公司證券上市規則》（以 下簡稱「《香港上市規則》」）和其他有關規定，制定本章程。 第二條 公司係依照《公司法》及中國境內其他法律法規、規範性文件成立的股份有限 公司。 公司係由無錫藥明康德新藥開發有限公司整體改制變更，以發起設立的方式設立，於 2017年3月1日在無錫市工商行政管理局註冊登記，取得公司營業執照，統一社會信用代 碼為91320200724183068U。 第三條 公司於2018年4月13日經中國證券監督管理委員會批准（以下簡稱「中國證監 會」），首次向社會公眾發行人民幣普通股10,419 ...